Soluble CD23 Expression in Asthma Patients Treated With OMA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00226200|
Recruitment Status : Terminated (Completed)
First Posted : September 26, 2005
Last Update Posted : December 1, 2008
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Omalizumab||Not Applicable|
This is a 1 year placebo controlled study looking at moderate to severe asthmatics (allergic or non-allergic) who are controlled by medication.
Skin testing will be done to determine the allergic status, as well as a base line IgE done. The Omalizumab is administered by injection based on weight and IgE level, (once or twice a month).
At several times during the year pulmonary function test will be done, as well blood drawn for immunological assays (CD23 and FcER1 expression, TH1/TH2 cytokines, CD23 production). A battery of questionnaires will also determine quality of life(with asthma), psychological stress measures and parameters of clinical response.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab|
|Study Start Date :||November 2004|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
- Measure of sCD23 in plasma
- CD23 expression on T cell correlated with spirometry, AQLQ and RQLQ.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226200
|United States, Mississippi|
|University of Mississippi Medical Center|
|Jackson, Mississippi, United States, 39216|
|Principal Investigator:||Gailen D Marshall, MD/PhD||University of Mississippi Medical Center|